2025

STRI filed approximately 1,800 additional KH Cells (KH Cells: a new type of pluripotent stem cell that does not form tumors but instead eliminates and suppresses cancer cells, while inducing down-aging effects) -related patents—including PCT applications—in 159 countries such as Korea, the United States, EU, Japan, and Australia and etc.
As a result, STRI has registered and applied a total of around 2,000 KHC patents.

Expansion and Relocation of the STRI

STRI published the research article : Efficacy and safety of umbilical cord-derived mesenchymal stem cell-conditioned media for preventing and treating skin aging : DOI: 10.4252/wjsc.v17.i9.108049

2023

STRI published the research article :1. Recovery from BEll’s palsy after treatment using uncultured umbilical cord-derived mesenchymal stem cells: A case report”. World J Clin Cases. 2023 April 26;11(12):2817-2824. DOI : 10.12998/wjcc.v11.i12.2817

2022

Approval Cell Facility Lisencse from Japan FDA

STRI published the research article :1. Treatment of syringomyelia using uncultured umbilical cord mesenchymal stem cells: A case report and review of literature World J Stem Cells. 2022 April 26; 14(4): 303-309. DOI: 10.4252/wjsc.v14.i4.303

2021

Approval Cell Facility License from KFDA

Approval Human Cell-Related Operation License from KFDA

STRI published the research articles :1. “Treatment of acute ischemic stroke by minimally manipulated umbilical cord-derived mesenchymal stem cells transplantation: A case report”. World J Stem Cells. 2021 Aug 26;13(8):1151-1159. doi: 10.4252/wjsc.v13.i8.1151.

2. “Psoriasis treatment using minimally manipulated umbilical cord-derived mesenchymal stem cells: A case report”. World J Clin Cases. 2021 Aug 16;9(23):6798-6803. doi: 10.12998/wjcc.v9.i23.6798.

3. “Alopecia treatment using minimally manipulated human umbilical cord-derived mesenchymal stem cells: Three case reports and review of literature”. World J Clin Cases 2021; 9(15): 3741-3751 [PMID: 34046478 DOI: 10.12998/wjcc.v9.i15.3741].

2020

STRI has applied 470 patents related with KHSc over 147 countries and 309 patents are registered in US,EU,Israel, Singapore, Russia, China etc.

2016

Running emergency pre-clinical tests with a prominent university for liver cirrhosis, liver and pancreatic cancer patients.

Signed MOU for collaborative research with Germany’s Fraunhofer Institute, to run preclinical on Alzheimer’s Disease.

2013

Discovered world’s first pluripotent stem cell without side effects(KHSc) and applied for domestic and overseas patents.

2007

Research arm expands into the Stem Cell Treatment & Research Institute

STC Nara receives CGMP certification

2000

Established STC fundamental science department

Certified as a R&D center affiliated with STC Life Science Research Center (Korea Industrial Technology Association(KOITA)

Established 3 sub divisions under STC Fundamental Science Department

STC Agricultural Life Science Research Center built a plant factory

1999

Expanded as to STC Life Science Research Center

1998

Established STC Biotech in USA

1997

STC Nara built a manufacturing plant in Cheonan

1995

Established STC Agricultural Life Science Research Center

1992

Established STC Nara(responsible for research activities for cell medicine, and manufacturing cosmetics and food supplements)

1989

Established STC Life Science Research laboratory (with the core value of Soul, Treatment & Cell – to contribute to mankind by developing cell medicine with a righteous mind)